Clinical Trial Search

Primary: Percentage of Participants Experiencing Any Infusion-related Reaction (IRR) Associated With the Second Rituximab Infusion — 6.5 percentage of participants

Primary: Best Corrected logMAR Contrast Acuity at Photopic/Mesopic Condition — 0.34; 0.34 log MAR

Primary: Percent Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26 — 8.02; 9.50 Percent change

Primary: Depression as Assessed by the Quick Inventory of Depressive Symptomatology-Self Rated 16 (QIDS-SR-16) — 6; 16 participants

Primary: Percentages of Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With HPV and MenACWY-CRM…

Primary: Incidence of POD — 2; 4 participants

Primary: Short PTSD Rating Interview (SPRINT) — 16.13; 19.88 units on a scale

Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass

Primary: Fasting Blood Glucose (FBS) Level (if Fasting Blood Glucose Level Was Not Available, Non-fasting Blood Glucose (Non-FBS) Level) — 0; 0; 1; 4 participants

Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants

Primary: Serum Progesterone (P4) Level in the Morning of the Day of Human Chorionic Gonadotrophin (hCG) Administration — 0.69; 0.72; 0.54; 0.89 ng/ml — p=0.003

Primary: Positive Reactions: Nickel Sulfate — 30 participants

Primary: Cessation of Bleeding Within 5 Days — 48 participants

Primary: Change in Weight From Baseline at 12 Months — 1.1; 1.9 kilograms

Primary: Time to First Event (Death, Stroke, Major Bleed) — 0.0785; 0.0987; 0.1542; 0.1820 cumulative probability of event — p=0.14